Insulin-expressing engineered cell lines and primary cells: surrogate ß cells from liver, gut, and other sources.
Curr Opin Organ Transplant
; 12(1): 67-72, 2007 Feb.
Article
en En
| MEDLINE
| ID: mdl-27792092
PURPOSE OF REVIEW: Islet transplantation is being used to treat type 1 diabetes but is currently limited by the shortage of tissue available and by insufficient long-term function of transplanted islets. Thus, there remains significant interest in developing substitute sources of insulin-producing cells. Here we review progress in this area, focusing on insulin gene therapy and generation of new insulin-producing cells by redirecting hepatic and intestinal tissues towards a ß-cell phenotype. RECENT FINDINGS: Insulin gene therapy using non-ß cells has been improved by utilizing modified insulin constructs controlled by regulatory elements to confer nutrient responsiveness, and by inducing insulin production in endocrine cells that are equipped for rapid and in some cases glucose-responsive secretion. Significant advances have also been made towards generation of insulin-producing cells via transcriptional manipulation of hepatic and intestinal cells. These approaches offer the potential of generating a virtually limitless supply of insulin-producing cells. SUMMARY: The major challenge associated with insulin gene therapy in non-ß cells is to achieve rapid, glucose-responsive secretion, while transdifferentiation approaches require additional characterization of the function and stability of insulin-producing cells. Continued efforts in these areas are warranted, as re-establishment of endogenous insulin production would be a welcome replacement to insulin injections for diabetes treatment.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Curr Opin Organ Transplant
Año:
2007
Tipo del documento:
Article
País de afiliación:
Canadá
Pais de publicación:
Estados Unidos